可变剪切对非小细胞肺癌患者的临床预后分析及验证

号通路在内的完整作用机制，并在组织样本中进行了初步验证。此外，为了拓展可变剪切在临床上的应用，我们将可变剪切的风险比例回归模型与临床指标结合起来，可以用于预测病人早期复发和肿瘤预后。综上所述，我们的研究对探索转录本的多样性对非小细胞肺癌的产生和发展的影响具有重要意义，我们所发现的各个独立预后因素均可作为后续研究的方向，临床模型也将指导临床医生判断患者肿瘤的预后和复发情况。硕士研究生：指导教师：关键词：可变剪切；非小细胞肺癌；预后；Analysis of the relationship between the alternative splicing and theprognosis of patients in non-small cell lung cancerAbstractObjective:Globally,lung cancer is identified as the most frequently occurring malignanttumor with the highest mortality.Among them,85%of these patients can be classified asnon-small cell lung cancer (NSCLC).In the past ten years,a large variety of targeteddrugs have been marketed one after another,but why do patients'benefits differ greatlywhen they are targeted at the same target?Recently,researchers have found thatalternative splicing is common in tumors.Alternative splicing is fundamental totranscriptome and proteome richness,and data from recently studies suggested a criticalassociation between alternative splicing and oncogenic processes.At present,there arelittle related researches on alternative splicing in NSCLC.Therefore,in order to find itsimpact on tumor prognosis and the mechanism of action,we conducted this study.Methods:RNA transcriptome profiling,sequence data and clinic data of LUAD andLUSC group were retrieved from The Cancer Genome Atlasl(https://tcga-data.nci.nih.gov/).Besides,real-time quantitative PCR was conducted tovalidate the selected OS-associated DEAS events.Firstly,we screen TCGA cases by setting strict criteria and divide LUAD and LUSC intotwo subgroups according to gender.Process sequencing data through TCGA SpliceSeqsoftware to obtain the patient's PSI.Then,the data was matched with clinical and